Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BiPar At The Center Of Sanofi's Efforts To Rebuild Its Oncology Business

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III PARP inhibitor for triple-negative breast cancer leads Sanofi's efforts to restock its oncology pipeline.

You may also be interested in...



Sanofi's PARP Inhibitor Plus Chemo May Be A Lethal One-Two Punch In Triple-Negative Breast Cancer

News that Sanofi-Aventis' PARP inhibitor iniparib conferred "significant clinical benefit" in a proof of concept study against metastatic triple-negative breast cancer – published online Jan. 5 by the New England Journal of Medicine – has generated excitement about the approach, but a Phase III study powered for statistically meaningful results in overall and progression-free survival will tell the tale.

Sanofi's PARP Inhibitor Plus Chemo May Be A Lethal One-Two Punch In Triple-Negative Breast Cancer

News that Sanofi-Aventis' PARP inhibitor iniparib conferred "significant clinical benefit" in a proof of concept study against metastatic triple-negative breast cancer – published online Jan. 5 by the New England Journal of Medicine – has generated excitement about the approach, but a Phase III study powered for statistically meaningful results in overall and progression-free survival will tell the tale.

Sanofi Bulks Up Oncology Development With Avila Collaboration

Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.

Related Content

Topics

UsernamePublicRestriction

Register

PS071288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel